Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men

Effect of Skin Metabolism on Dermal Delivery of Testosterone: Qualitative Assessment using a New Short-Term Skin Model

“…The biological effects of androgens are numerous, and testosterone deficiency is associated with a number of clinical abnormalities. A variety of preparations containing testosterone, such as oral tablets, intramuscular injections, subcutaneous implants and transdermal application, is available as substitution therapy of climacteric symptoms as well as hypogonadism [1,2]. Among the several possible administration routes for testosterone, transdermal delivery offers advantages over oral administration, in that hepatic first-pass metabolism in the liver occurs for the oral route, which requires higher testosterone doses.…”

Comparison of oral versus transdermal testosterone supplementation in hypogonadal men

“…The kinetics of the two products being different (32,34), blood sampling times were defined to allow comparison: 4 h after intake during breakfast (what is generally considered the time of the peak for testosterone concentration after Pantestone intake) and 24 h, each day of sampling.…”

“…Testopatch ᭨ is an innovative testosterone transdermal system to overcome the limitations of existing formulations (31)(32)(33). The aim of this study was therefore to compare Testopatch ᭨ vs. Pantestone ᭨ in terms of serum level restoration of sex hormones (testosterone, bioavailable-testosterone, dihydrotestosterone, oestradiol).…”

Late-onset hypogonadism or ADAM: treatment

“…At a dose of 5 to 7.5 mg/day, changing patches every 48 hours, they are capable of producing a significant improvement in symptoms and quality of life of patients with ADAM (A) 8 (B). [45][46][47] With respect to security, Raynaud et al 44,47 reported that the use of transdermal patches showed no negative impact on the hematocrit and lipid profile of patients (B), 45 and does not contaminate other people or the environment (B). 47 Many patients prefer transdermal gels or solutions as they are easy to apply, substantially free of local reactions and do not require injections (D).…”

“…[45][46][47] With respect to security, Raynaud et al 44,47 reported that the use of transdermal patches showed no negative impact on the hematocrit and lipid profile of patients (B), 45 and does not contaminate other people or the environment (B). 47 Many patients prefer transdermal gels or solutions as they are easy to apply, substantially free of local reactions and do not require injections (D). 41 Testosterone gel formulations available on the health market are available in the concentration of 1% as "pumps", so that each "puff" releases 1.25 g of product; individual 2.5 g and 5 g packages or single dose tubes containing 5 g of the product.…”